Johnson & Johnson (JNJ, Financial) Declares a cash payout of $1.24 dividend per share on common stock for first quarter 2025, payable on 4th of March 2025 to shareholders that recorded on 18th of February 2025.
Despite still dealing with ongoing litigation related to its talcum powder that is claimed to cause fatality to a woman, the number of short interests to this pharmaceutical giant dropped by 5.2% per December 2024 indicating approval from investors to JNJ's near future.
The recent investors' confidence is allegedly related to JNJ's newly approved drugs RYBREVANT® (amivantamab) in combination with LAZCLUZE® (lazertinib) by the European Commission for patients with EGFR-mutated advanced non-small cell lung cancer.
JNJ has strong history of dividend distribution since 1963 with dividend payout ratio of 0.47 that grows at CAGR 5.8% in 5 years. With no dividend payment failures, investors shall consider any occurrences as a buying-the-dip opportunity.
You can make more informed investment decision by visiting GuruFocus now and deep dive into Johnson and Johnson's performance with charts, breakdowns, 30-year financial data, and more!
